Table 1.
Comparisons of clinical characteristics of patients.
| Characteristic | HAIC (n = 57) | TACE (n = 69) | P |
|---|---|---|---|
| gender | |||
| male | 42 | 53 | 0.685 |
| female | 15 | 16 | |
| age | |||
| ≤60 | 42 | 48 | |
| >60 | 15 | 21 | 0.610 |
| Tumor size | |||
| ≤5 | 5 | 5 | 0.753 |
| >5 | 52 | 64 | |
| Vascular Invasion | |||
| Absence | 28 | 34 | 0.986 |
| Presence | 29 | 35 | |
| LN metastasis | |||
| Absence | 25 | 22 | 0.167 |
| Presence | 32 | 47 | |
| Distant metastasis | |||
| Absence | 37 | 43 | 0.763 |
| Presence | 20 | 26 | |
| TNM stage | |||
| II | 22 | 15 | 0.096 |
| IIIb | 15 | 28 | |
| IV | 20 | 26 | |
| WBC (E+09) | |||
| ≤10 | 40 | 50 | 0.777 |
| >10 | 17 | 19 | |
| HGB (g/L) | |||
| ≤120 | 14 | 18 | 0.845 |
| >120 | 43 | 51 | |
| PLT (E+09) | |||
| ≤300 | 45 | 56 | 0.757 |
| >300 | 12 | 13 | |
| ALB (g/L) | |||
| ≤40 | 24 | 34 | 0.422 |
| >40 | 33 | 35 | |
| ALT (U/L) | |||
| ≤50 | 43 | 56 | 0.436 |
| >50 | 14 | 13 | |
| AST (U/L) | |||
| ≤40 | 27 | 39 | 0.306 |
| >40 | 30 | 30 | |
| ALP (U/L) | |||
| ≤125 | 24 | 30 | 0.877 |
| >125 | 33 | 39 | |
| GGT (U/L) | |||
| ≤60 | 6 | 12 | 0.273 |
| >60 | 51 | 57 | |
| TBIL (umol/L) | |||
| ≤20.5 | 50 | 55 | 0.230 |
| >20.5 | 7 | 14 | |
| IBIL (umol/L) | |||
| ≤15 | 54 | 64 | 0.650 |
| >15 | 3 | 5 | |
| CRP (ng/L) | |||
| ≤3 | 7 | 7 | 0.704 |
| >3 | 50 | 62 | |
| AFP (ng/ml) | |||
| ≤25 | 38 | 42 | 0.501 |
| >25 | 19 | 27 | |
| CEA (ng/mL) | |||
| ≤5 | 34 | 46 | 0.415 |
| >5 | 23 | 23 | |
| CA19-9 (U/ml) | |||
| ≤35 | 17 | 24 | 0.517 |
| >35 | 40 | 44 | |
| HBsAg | |||
| negative | 24 | 30 | 0.831 |
| positive | 32 | 37 | |
| CA19-9 (U/ml) | |||
| ≤200 | 38 | 40 | 0.317 |
| >200 | 19 | 29 | |
| CA19-9effect | |||
| Negative before treatment | 15 | 14 | 0.720 |
| Decline after treatment | 24 | 15 | |
| No decline after treatment | 11 | 8 | |
| PIVKA-II(mAU/ml) | |||
| ≤40 | 34 | 20 | 0.698 |
| >40 | 17 | 12 | |